Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event
Stocks in this Quantisnow insightHealth Care
Historical context for SER
Across the 6 sessions after earlier SER headlines, the stock closed higher 2 times and lower 4 times, with a median move of 4.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SER | SPY |
|---|---|---|---|
| Jan 29, 2026 | Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease | +30.1% | -0.2% |
| Jan 16, 2026 | Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity | +15.2% | -0.1% |
| Dec 12, 2025 | Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry | -0.6% | -1.1% |
| Dec 11, 2025 | Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program | -2.2% | +0.2% |
| Nov 13, 2025 | Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights | -2.5% | -1.7% |
| Nov 3, 2025 | Serina Therapeutics Provides Regulatory Update on SER-252 Program | -6.4% | +0.2% |
Quantisnow market dataAMEX
SER
Serina Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for SER
Full SER profile on Quantisnow Follow SER and get a push notification the moment its next story breaks.